Novartis drug 78% efficient against COVID - trial

Monday, 10. January 2022 09:59

Novartis International AG and Molecular Partners AG announced on Monday that their COVID-19 treatment ensovibep has a 78% efficacy based on the first part of its clinical trial. The company stated it decided to exercise its option to in-license the drug from Molecular Partners and seek authorization from the United States Food and Drugs Administration (FDA).

The study included 407 patients and showed a "statistically significant reduction in viral load over eight days" compared to placebo. It also demonstrated 78% efficacy against events related to COVID-19, including hospitalization and death. Novartis stated that the two administered doses of the drug "were well-tolerated and no unexpected safety issues were identified." The data will undergo further review to "determine the appropriate next steps for the program."

Novartis gained 0.62% after the news, and Molecular Partners soared 29.21%.

Related Links: Molecular Partners AGNovartis AG
Baha Breaking News (BBN) / DJ